Abstract
Gene expression studies have suggested that dopamine (DA) depletion increases the sensitivity of striatal direct pathway neurons to the effects of serotonin (5-HT) via the 5-HT2 receptor. The present study examined the possible influence(s) of 5-HT2A or 5-HT2C receptor-mediated signaling locally within the striatum on motor behavior triggered by 5-HT2 receptor agonism in the neonatal DA-depleted rat. Male Sprague-Dawley rats were treated with 6-hydroxydopamine (6-OHDA; 60 μg in 5 μl per lateral ventricle) on postnatal day 3 to achieve near-total DA depletion bilaterally. Sixty days later, sham-operated (saline-injected) or 6-OHDA-treated rats were challenged with the 5-HT2A/2C agonist DOI [(±)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane] or saline either by systemic treatment or bilateral intrastriatal infusion. Motor behavior was quantified for 60 min after agonist injection using computerized activity monitors. Systemic DOI treatment (0.2 or 2.0 mg/kg i.p.) was more effective in inducing motor activity in the DA-depleted group compared with intact controls. Intrastriatal DOI infusion (1.0 or 10.0 μg/side) also produced a significant rise in motor activity in the DA-depleted group during the 30- to 60-min period of behavioral analysis but did not influence behavior in intact animals. The effects of intrastriatal DOI infusion were blocked by intrastriatal coinfusion of the 5-HT2 antagonist ketanserin (1.0 μg) and the 5-HT2A-preferring antagonist M100907 [(R)(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol; 1.0 μg] but not the 5-HT2C-preferring antagonist RS102221 [8-[5-(2,4-dimethoxy-5-(4-trifluoromethylsulfo-amido)phenyl-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione; 1.0 μg]. Such results support the hypothesis that 5-HT2A receptor-mediated signaling events are strengthened within the striatum under conditions of DA depletion to provide a more potent regulation of motor activity.
Footnotes
-
This work was supported by Grant NS39013 from the National Institute of Neurological Disorders and Stroke to P.D.W.
-
DOI: 10.1124/jpet.104.066365.
-
ABBREVIATIONS: DA, dopamine; 5-HT, 5-hydroxytryptamine (serotonin); PPT, preprotachykinin; DOI, (±)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane; 6-OHDA, 6-hydroxydopamine; M100907, (R)-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol; RS102221, 8-[5-(2,4-dimethoxy-5-(4-trifluoromethylsulfo-amido)phenyl-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione; ANOVA, analysis of variance; DOPAC, 3,4-dihydroxyphenlyacetic acid; 5-HIAA, 5-hydroxyindole-3-acetic acid.
-
↵1 Current Address: Novartis Research Institute, A-1235 Vienna, Austria.
- Received January 30, 2004.
- Accepted March 24, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|